The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combining low-dose regorafenib with pembrolizumab for patients with MSI-H colorectal cancer: REGPEM-CRC-01- HCRN GI23-643.
 
Ibrahim Sahin
Consulting or Advisory Role - GlaxoSmithKline; Guardant Health; Seagen
Speakers' Bureau - Amgen; Pfizer
 
Stacey Cohen
Consulting or Advisory Role - Abbvie; Agenus; Caris Life Sciences; DoMore Diagnostics; Exact Sciences; GlaxoSmithKline; Guardant Health; Incyte; Janssen; Merck; Pfizer; Roche Molecular Diagnostics
Research Funding - Biomea (Inst); BioNTech SE (Inst); Natera (Inst); Pfizer (Inst); Tempus (Inst)
Expert Testimony - Brewster & DeAngelis; Mac Ban; Power Rogers; The Cline Law Firm
 
Pashtoon Kasi
Leadership - Precision Biosensors
Stock and Other Ownership Interests - Elicio Therapeutics
Consulting or Advisory Role - Agenus; Astellas Pharma; Bayer; BeiGene; BostonGene; BostonGene; Daiichi Sankyo/Astra Zeneca; Delcath Systems; Eisai; Elicio Therapeutics; Exact Sciences; Foundation Medicine; Guardant Health; Illumina; Ipsen (Inst); Lilly; MSD Oncology; Natera; NeoGenomics Laboratories; QED Therapeutics; Regeneron; SAGA Diagnostics; Seagen; SERVIER; Taiho Oncology; Taiho Pharmaceutical (Inst); Tempus; Xilio Therapeutics
Research Funding - Advanced Accelerator Applications (Inst); Agenus (Inst); Boston Scientific (Inst); Merck (Inst); Tersera (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Shikha Jain
Stock and Other Ownership Interests - Doximity
Honoraria - Genentech; Healio; Jazz Pharmaceuticals; Magellan Health; Novartis; Pfizer; Tempus
Consulting or Advisory Role - Healio; Magellan Health
Speakers' Bureau - Practicing Clinician Exchange
Travel, Accommodations, Expenses - MJH Life Sciences
 
Mohamedtaki Tejani
No Relationships to Disclose
 
Rachael Safyan
Honoraria - Oncology State Societies at ACCC; Oncology State Societies at ACCC
Consulting or Advisory Role - Agenus; Guardant Health; Ipsen; Mirati Therapeutics
Research Funding - Amgen (Inst); Exelixis (Inst); J&J (Inst); Replimune (Inst); Verastem (Inst)
 
E. Gabriela Chiorean
No Relationships to Disclose
 
Vikram Gorantla
Consulting or Advisory Role - AstraZeneca
 
Patrick Boland
Consulting or Advisory Role - Abbvie; BeiGene; Bristol Myers Squibb Foundation; Incyte; Incyte; Taiho Oncology
Research Funding - Caris Life Sciences (Inst); Compass Therapeutics (Inst); MEI Pharma (Inst); Merck (Inst); Processa Pharmaceuticals (Inst)
 
Richard Kim
Honoraria - Natera
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Eisai; Exelixis; Jazz Pharmaceuticals; Pfizer; Roche/Genentech; SERVIER; Taiho Oncology
Speakers' Bureau - AstraZeneca; Incyte
 
Anwaar Saeed
Consulting or Advisory Role - Arcus therapeutics; Astellas Pharma; AstraZeneca; Autem therapeutics; Autem Therapeutics; BeOne therapeutics; Bristol-Myers Squibb; Exelixis; Pfizer; Regeneron; Replimune; Taiho Pharmaceutical; Xilio therapeutics
Research Funding - Actuate Therapeutics (Inst); Arcus therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeOne therapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Incyte (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Oxford biotherapeutics (Inst); Phanes Therapeutics (Inst); Replimune (Inst)